Business
NovaBay Pharmaceuticals to Present at the New York Society of Security Analysts Biotech/Specialty Pharma Conference
Presentation to be Made on Tuesday, December 11, 2007 at 3:30PM/EST EMERYVILLE, CALIF., December ...
About this update from Niobay Metals Inc.
[{"type":"text","content":"\n\n\n\nPresentation to be Made on Tuesday, December 11, 2007 at 3:30PM/EST\n\n\nEMERYVILLE, CALIF., December 4 /CNW/ - NovaBay Pharmaceuticals, Inc.\n(AMEX & TSX: NBY, http://www.novabaypharma.com), a biopharmaceutical company\ndeveloping products for the treatment or prevention of a wide range of\nbacterial and viral infections, will present at the New York Society of\nSecurity Analysts' ("NYSSA") 11th Annual Biotech/Specialty Pharma Conference\nheld at the NYSSA's headquarters in New York City on Tuesday, December 11 at\n3:30PM/EST. The live PowerPoint presentation with streaming video will be\nwebcast and archived for one year at:\nhttp://investor.shareholder.com/media/eventdetail.cfm?eventid(equal sign)47195&\nCompanyID(equal sign)NBY&e(equal sign)1&mediaKey(equal sign)79860443FCCAECCD93F3C3F9401CFB25.\n\n\n(Due to its length, this URL may need to be copied/pasted into your\nInternet browser's address field. Remove the extra space if one exists.)\n\n\nJack O'Reilly, NovaBay's SVP, Corporate Development and Chief Financial\nOfficer, will provide an overview of the company's clinical development\nprograms and the status of its licensing agreements with affiliates of Alcon,\nInc. (NYSE: ACL) and Kinetic Concepts, Inc. (NYSE:KCI). Mr. O'Reilly will also\nhighlight NovaBay's recently reported positive Phase I safety results for its\nlead Aganocide compound, NVC-422, a novel non-antibiotic anti-infective that\nhas shown potent in vitro activity against major pathogens, including\nmethicillin-resistant Staphylococcus aureus (MRSA).\n\n\nCalifornia based NovaBay recently closed an initial public offering (IPO)\nof common stock on October 31, 2007, and is dually listed on the American\nStock Exchange and the Toronto Stock Exchange under the symbol "NBY."\n\n\nAbout NovaBay Pharmaceuticals, Inc.\n\n\nNovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on\ndeveloping innovative product candidates targeting the treatment or prevention\nof a wide range of infections in hospital and non-hospital environments.\nNovaBay has discovered and is developing a class of non-antibiotic\nanti-infective compounds, which it has named Aganocide compounds, based upon\nsmall molecules that are generated by white blood cells that defend the body\nagainst invading pathogens. NovaBay believes that Aganoc...